Beigene Ltd (NASDAQ:BGNE) shares dropped 0.5% during trading on Monday . The stock traded as low as $27.40 and last traded at $28.00, with a volume of 55,823 shares. The stock had previously closed at $28.15.

BGNE has been the subject of several analyst reports. Cowen and Company reaffirmed a “buy” rating on shares of Beigene in a report on Monday, June 6th. Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a report on Monday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $39.67.

The stock’s market capitalization is $955.19 million. The company’s 50-day moving average is $28.15 and its 200 day moving average is $28.72.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.05. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $2.08 million. The firm’s quarterly revenue was down 71.4% compared to the same quarter last year. On average, analysts anticipate that Beigene Ltd will post ($3.31) earnings per share for the current year.

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.